AD/PD 2024 | The potential of cell and gene therapy in treating Parkinson’s disease

Fabrizio Stocchi, MD, PhD, IRCCS San Raffaele Rome,Sapienza University of Rome, discusses the potential of cell therapy in treating Parkinson’s disease (PD). Recent Phase I data from a trial of implanted dopaminergic neuron precursors derived from human embryonic stem cells showed excellent safety, with no side effects reported after a year. In additional exploratory analyses, patients demonstrated improvements in Unified Parkinson’s disease rating scale (UPDRS) scores and daily function. While gene therapy shows promise, early trials have yielded mixed results. New data from upcoming studies will shed more light on its effectiveness. This interview took place at the AD/PD™ 2024 congress in Lisbon, Portugal.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.